Wells Fargo raised its price target on Cigna (NYSE: CI) to $325 from $307 while keeping an Equal Weight rating. The stock trades at $296.27. The bank lowered 2027 and 2028 earnings per share estimates to $33.30 and $36.30 from $33.77 and $36.92, respectively, reflecting a $0.60 reduction due to the health insurance exchange exit and stranded costs.
Wells Fargo increased the price target despite lower estimates because it applied less discounting to future earnings. Cigna committed to at least 10% EPS growth in 2027 based on a roughly $30 run-rate that excludes approximately $200 million of ACA exchange contribution and stranded costs from the at least $30.60 2026 guidance.
Cigna guided Evernorth adjusted operating income up low single digits, with pharmacy benefit services down single digits and specialty and care solutions toward the low end of 8% to 12%. Cigna Healthcare adjusted operating income is expected to rise 6% to 9% off reported 2026 results.
Cigna reported third-quarter adjusted earnings of $7.98 per share on revenue of $73.7 billion, beating Wall Street estimates of $7.52 per share and $72.65 billion. The company raised its full-year adjusted earnings outlook to at least $30.60 per share. Piper Sandler lowered its price target for Cigna to $360, citing concerns over rebate pool contraction and declining commercial coverage of certain medications. Bernstein SocGen Group raised its price target to $390, maintaining an Outperform rating and expressing confidence in Cigna's 2027 growth outlook.
Investors monitoring CI should watch for formal 2027 guidance when Cigna reports fourth-quarter 2026 results in early 2027.